Orphan Medical Issues Xyrem Prescriptions Update

MINNEAPOLIS–(BUSINESS WIRE)–Feb. 23, 2005–Orphan Medical, Inc. (Nasdaq:ORPH) announced that the total number of Xyrem(R) (sodium oxybate) oral solution prescriptions filled in the six-week period ended…

Sepracor Announces Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of Insomnia

MARLBOROUGH, Mass., April 1, 2005 /PRNewswire-FirstCall via COMTEX/ — Sepracor Inc. (Nasdaq: SEPR) today announced that the final rule that will designate eszopiclone as a…

New Study Shows Lyrica Helps Reduce Fibromyalgia Pain

Source: University of Kentucky University of Kentucky physician publishes fibromyalgia study in Arthritis & Rheumatism journal LEXINGTON, Ky. (April 12, 2005) – A study of…

FDA MedWatch – COX-2 Selective and Non-Selective NSAIDs : Safety labeling changes

MedWatch – The FDA Safety Information and Adverse Event Reporting Program FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes…

Improved Awareness of Fibromyalgia by Both Physicians and Patients Will Drive the Drug Market, According to a New Study from Decision Resources

Although the Fibromyalgia Market Will More Than Triple in Size Over the Next Decade, it Will Remain Small in Comparison with Primary Target Markets Such…

Case Raises New Concern Over Withdrawal of Drugs: Lyrica (Pregabalin)

By NICHOLAS BAKALAR In recent years, many anticonvulsant drugs have been widely prescribed not only for seizure disorders, but for various kinds of chronic pain…

AMBIEN CR(TM) (Zolpidem Tartrate Extended-Release Tablets) CIV Receives FDA Approval for the Treatment of Insomnia

First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population BRIDGEWATER, N.J., Sept. 6 /PRNewswire-FirstCall/ — Sanofi-aventis (NYSE:…

FDA Approves REMICADE® (infliximab) as First and Only Biologic to Treat Ulcerative Colitis

Approval Marks Major Treatment Breakthrough for Patients With Debilitating Disease Horsham, PA (September 16, 2005) – Centocor, Inc., announced today that REMICADE® (infliximab) has been…

Randomized Double Blind Clinical Study Shows Improvement for 90% of Fibromyalgia Patients Using Swiss Medica’s O24 Pain Relief Product

Toronto, Canada – Pursuant to the Company’s December 22nd (2004) News Release, Swiss Medica is pleased to announce the results of the randomized double blind…

NEURAGEN PN Receives FDA Approval for Pain Relief

HALIFAX, Nova Scotia, Canada (September 7, 2005) – Origin BioMedicinals Inc. announced today that it has received US FDA registration for its pain relief product…